GlassScriptPhysician profile
Jennifer Lane
NPI 1467744680
$3,444.27
in general payments reported to CMS, 2019-2025
36 companies · $49.19 in 2025
The $49.19 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,559 · 2022: $913 · 2023: $759 · 2024: $164 · 2025: $49.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $563.95 | 2021-2024 | Mounjaro, Trulicity |
| Novo Nordisk INC | $404.93 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.33 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $228.48 | 2021-2024 | |
| Glaxosmithkline, LLC. | $213.57 | 2021-2023 | Shingrix, Arexvy |
| Pfizer INC. | $204.26 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $168.88 | 2022-2023 | Camzyos, Eliquis |
| Amgen INC. | $154.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.58 | 2021-2023 | Farxiga, Breztri |
| Abbvie INC. | $135.38 | 2021-2024 | |
| Amarin Pharma, INC. | $122.58 | 2021-2022 | |
| Dexcom, INC. | $121.21 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $74.82 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.09 | 2022 | |
| Esperion Therapeutics, INC. | $65.18 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $52.79 | 2021 | |
| Mylan Specialty L.P. | $49.03 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.24 | 2021 | |
| Merck Sharp & Dohme LLC | $36.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.48 | 2021-2022 | |
| Halozyme INC | $27.18 | 2023 | |
| Tris Pharma INC | $23.50 | 2023 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $23.32 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $22.72 | 2023 | Injectafer |
| Astellas Pharma US INC | $21.85 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $21.48 | 2023 | Inspire |
| Exact Sciences Corporation | $20.31 | 2025 | The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $18.06 | 2022 | |
| Medtronic, INC. | $17.73 | 2021 | |
| Eisai INC. | $17.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.48 | 2022 | |
| Dynavax Technologies Corporation | $14.16 | 2023 | Heplisav-B |
| Abbott Laboratories | $13.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.50 | 2021 | |
| Ibsa Pharma INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.